According to the latest market analysis by Future Market Insights, the global nasal sprays market is poised for consistent ...

Despite its scale, steatotic liver disease remains largely absent from global and US noncommunicable disease strategies.

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in ...

According to the latest market analysis by Future Market Insights, the global nasal sprays market is poised for consistent expansion, supported by ...

If the government wants to pay more for medicines as part of its trade policy it should fund that choice explicitly, say ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from ...

A single infusion of ciltacabtagene autoleucel (Carvykti) led to a 100% minimal residual disease (MRD)-negativity rate in patients with ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors ...

In today's rapidly evolving business environment, a remarkable group of entrepreneurs is leading the way with innovative ...

Discussion at the Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2026 recognises that artificial ...

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy linerixibat, which is under regulatory review in most major pharma markets worldwide ...

The steady stream of M&A deals in pharma this year has continued with the news that GSK has agreed to buy Canada's 35Pharma and its drug candidate for pulmonary hypertension (PH) for $950 million. The ...